Advitech Inc.
TSX VENTURE : AVI

Advitech Inc.

October 03, 2005 09:00 ET

Advitech to Communicate the Results of its Study on Inflammatory Bowel Diseases October 6, at Biocontact 2005

QUEBEC CITY, QUEBEC--(CCNMatthews - Oct. 03, 2005) - Advitech Inc. (TSX VENTURE:AVI) today announced that Michel Lamontagne, Vice-President and Chief Financial Officer, will make a presentation at the upcoming BioContact 2005 investor conference to be held on October 5 to 7, 2005, in Quebec City. The presentation is scheduled for October 6, 2005, at 4:30 p.m. ET, at the Chateau Frontenac, room Petit Frontenac, in Quebec City.

Vice-President Lamontagne will update the investment community on the recent developments of the Company. He will also present the results of the now completed preclinical study on inflammatory bowel diseases, the second application of the XP-828L platform for chronic inflammatory disorders. The Company is expected to issue a press release on October 6, to communicate the results of this study to the investment community. Mr. Lamontagne will be available to comment on these results at the BioContact conference.

The presentation will be posted on Advitech's website at www.advitech.com after the event. BioContact is a partnership symposium at which over 150 companies make presentations to more than 1200 participants.

About Advitech

Advitech is a Canadian biotechnology company specializing in the development of treatments for chronic immune-mediated inflammatory diseases (I.M.I.D.). Its main platform, XP-828L, is a patented natural growth factor composition derived from dairy proteins with immuno-modulating properties. Advitech's common shares are listed on the TSX Venture Exchange under the symbol AVI. The number of common shares outstanding is 54,799,818.

This press release contains forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein.

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.

Contact Information

  • Advitech Inc.
    Michel Lamontagne, MBA
    Vice-President and Chief Financial Officer
    (418) 686-7498, ext. 237
    Email: m.lamontagne@advitech.com
    Website: www.advitech.com
    or
    Echoes Financial Network Inc.
    Dominic Sicotte
    Media and Investors
    (514) 842-9551, ext. 236
    or
    Echoes Financial Network Inc.
    Martin Lavoie
    Media and Investors
    (514) 842-9551, ext. 231
    Website: www.roadshows.tv